Simak Ali

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Emory University, Cancer Research Technology Limited, Imperial Innovations Limited. Active years: 2007-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simak Ali. Retrieved from https://idiyas.com/inventor/simak-ali

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 24(Granted Patents)

Company Filing History:

Cancer Research Technology Limited

patents

2 out of 167

Imperial Innovations Limited

patents

4. 2 out of 52

Ip2ipo Innovations Limited

patents

5. 1 out of 1

Gene Expression Technologies Limited

patent

6. 1 out of 112

Imperial College of Science, Technology and Medicine

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11566029 - Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use (2023-01-31),

2. 10927119 - Pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use (2021-02-23),

3. 10414772 - Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use (2019-09-17),

4. 9932344 - Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use (2018-04-03),

5. 8067424 - Selective inhibitors for cyclin-dependent kinases (2011-11-29),

6. 7202025 - Control of gene expression (2007-04-10),

Title: Simak Ali: Innovator in CDK Inhibition

Introduction

Simak Ali is a prominent inventor based in London, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDKs). With a total of 6 patents to his name, Ali's work has the potential to impact various therapeutic areas.

Latest Patents

One of Simak Ali's latest patents involves pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors. These compounds are designed to inhibit various CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patent outlines pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischaemia, renal diseases, and cardiovascular disorders. The treatment may also include simultaneous or sequential administration of additional active agents, such as aromatase inhibitors or cytotoxic chemotherapeutic agents.

Career Highlights

Throughout his career, Simak Ali has worked with esteemed institutions, including Emory University and Cancer Research Technology Limited. His research has focused on the therapeutic applications of CDK inhibitors, contributing to advancements in cancer treatment and other related fields.

Collaborations

Some of his notable coworkers include James P Snyder and Alexander Bondke. Their collaborative efforts have furthered the research and development of innovative therapeutic solutions.

Conclusion

Simak Ali's contributions to the field of medicinal chemistry, particularly in the area of CDK inhibition, highlight his role as a key innovator. His patents and collaborations reflect a commitment to advancing therapeutic options for various diseases.

Profile summary based on public USPTO records.